



Regulatory T Cells in Neuroimmunological Disease Therapeutics

Guest Editor:

Dr. Michel Edwar Mickael

Department of Experimental
Genomics, Institute of Genetics
and Animal Biotechnology,
Polish Academy of Sciences,
Postępu 36A, 05-552 Garbatka,
Poland

Deadline for manuscript
submissions:

31 July 2024

Message from the Guest Editor

Topics of Interest:

- **Autoimmune Diseases:** Explore the involvement of Tregs in autoimmune neuroimmunological diseases. Investigate Treg-based therapies aimed at modulating autoimmunity.
- **Immunomodulation:** Examine how Tregs can be harnessed to modulate the immune responses contributing to neuroinflammation. Discuss the impact of existing immunomodulatory therapies on Treg function.
- **Neuroprotection:** Investigate the neuroprotective effects of Tregs in various neuroimmunological diseases. Explore how Tregs can limit immune-mediated neuronal damage, reduce inflammation, and support tissue repair.
- **Immune–Brain Crosstalk:** Delve into the role of Tregs in influencing the communication between the immune system and the central nervous system. Explore Treg-based approaches for conditions associated with gut dysbiosis, such as autism spectrum disorders and mood disorders.
- **Treg-Based Therapies:** Present research on Treg-based therapies tailored to specific neuroimmunological diseases. Discuss strategies for Treg isolation, expansion, and administration, as well as the potential of genetically modified Tregs.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)